Rate My Professor Mhairi Copland
Ratings & reviews
MARK DRUMMAND AT BEATSON CANCER WAS AMAZING pity he is retired now MHAIRA CANTCOPELAND should stick to research if she wants to help people its amazing that someone like mhaira can be in charge of a whole department whos lives depend on her .
MARK DRUMMAND AT BEATSON CANCER WAS AMAZING pity he is retired now MHAIRA CANTCOPELAND should stick to research if she wants to help people its amazing that someone like mhaira can be in charge of a whole department whos lives depend on her .
MARK DRUMMAND AT BEATSON CANCER WAS AMAZING pity he is retired now MHAIRA CANTCOPELAND should stick to research if she wants to help people its amazing that someone like mhaira can be in charge of a whole department whos lives depend on her
Creates a positive and welcoming vibe.
Taught by or worked with Mhairi?
Add your rating. It takes about 30 seconds.
About Mhairi
Professor Mhairi Copland is Professor of Translational Haematology in the School of Cancer Sciences at the University of Glasgow, where she directs the Paul O'Gorman Leukaemia Research Centre. She also holds an honorary consultant haematologist position at the Beatson West of Scotland Cancer Centre, supporting myeloid, teenage and young adult cancer services, and the clinical research unit. Copland earned her BSc (hons) and MB ChB from the University of Aberdeen in 1996, relocated to Glasgow in 1999 as a clinical trainee in haematology, and was appointed Clinical Senior Lecturer and Honorary Consultant in 2008. She completed her PhD in Cancer Sciences at the University of Glasgow in 2007 and founded the Leukaemia Stem Cell Self-Renewal group that same year. As Head of the Experimental Haematology Section and former Chair of the UK NCRI Chronic Myeloid Leukaemia (CML) Subgroup, she leads the Bloodwise Trials Acceleration Programme at the Beatson and serves as principal investigator for multiple acute leukaemia trials.
Copland's research centres on leukaemia stem cells in myeloid malignancies, particularly chronic myeloid leukaemia (CML) and acute myeloid leukaemia (AML), examining self-renewal abnormalities, bone marrow microenvironment interactions, Hedgehog pathway activation, quiescence-mediated drug resistance, and the CXCL12/CXCR4 axis. Her laboratory explores molecular pathways, immune evasion, mitochondrial metabolism, and novel in vitro bone marrow niche models for diagnostic and therapeutic applications. She translates these findings into clinical trials, acting as chief investigator for the Phase 1 MATCHPOINT trial (ponatinib with chemotherapy in CML), Phase 2 TASTER trial, and DESTINY trial (therapy reduction prior to treatment-free remission in CML), and co-chief investigator for LI-1 (novel therapies in elderly AML). Her work has produced over 250 publications, including recent contributions such as 'A metabolism-specific drug-repurposing screen reveals itraconazole as a potent OXPHOS inhibitor in acute myeloid leukemia' (Blood, 2026), 'Sequential BCR::ABL1 evaluation during dose de-escalation in peripheral blood is more predictive of TFR success' (Leukemia, 2026), and 'Venetoclax-based non-intensive combinations for relapsed/refractory acute myeloid leukaemia' (British Journal of Haematology, 2025). Funded by Bloodwise and Cancer Research UK, her efforts maintain the centre's international reputation while mentoring early-career researchers in laboratory studies, trial design, and patient involvement.
Trending Research & Publication News
SPARC Cost of Knowledge Study: 95% Public Investment in Articles
Photo by Precondo CA on Unsplash
AI Research Scooping: OpenAI & Anthropic Priority Disputes
Photo by Brecht Corbeel on Unsplash
Informa Taylor & Francis Split & Clarion Deal | AcademicJobs
Photo by Anne Nygård on Unsplash
arXiv Two-Submission Monthly Cap Explained | AcademicJobs
Photo by Kelly Sikkema on Unsplash
Cell Press Bribery Investigation: Cancer Cell Editor Accused
Photo by Markus Winkler on Unsplash
Society Journal Sales & Nonprofit Consolidations | AcademicJobs
Photo by Philip Strong on Unsplash